Monocyte lineage–derived IL-6 does not affect chimeric antigen receptor T-cell function

Cytotherapy

Volumn 19, Issue 7, 2017, Pages 867-880

  Singh, Nathan ^a   Hofmann, Ted J ^b   Gershenson, Zachary ^a   Levine, Bruce L ^c   Grupp, Stephan A ^b,c   Teachey, David T ^b   Barrett, David M ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

chimeric antigen receptor; cytokine release syndrome; interleukin 6

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD22 ANTIGEN; CD24 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CD79A ANTIGEN; CD79B ANTIGEN; CD81 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; LYMPHOID ENHANCER FACTOR 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; T6 ANTIGEN; TISAGENLECLEUCEL T; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR TCF4; UNCLASSIFIED DRUG; CD19 MOLECULE, HUMAN; CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; IL6 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CELL CONTACT; CELL LINEAGE; CELL MEDIATED CYTOTOXICITY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DENDRITIC CELL; DRUG EFFICACY; DRUG TARGETING; DRUG TREATMENT FAILURE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ANIMAL; DRUG SCREENING; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NONOBESE DIABETIC MOUSE; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD19; CELL LINEAGE; COCULTURE TECHNIQUES; CYTOKINES; HUMANS; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MICE, INBRED NOD; MONOCYTES; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019080872     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2017.04.001     Document Type: Article

References (24)

1. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:16 (2013), 1509–1518.
2. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 6(224), 2014, 224ra25.
3. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:9967 (2015), 517–528.
4. Schulert, G.S., Grom, A.A., Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu Rev Med 66 (2015), 145–159.
5. Leech, M.D., Barr, T.A., Turner, D.G., Brown, S., O'Connor, R.A., Gray, D., et al. Cutting edge: IL-6-dependent autoimmune disease: dendritic cells as a sufficient, but transient, source. J Immunol 190:3 (2013), 881–885.
6. Barr, T.A., Shen, P., Brown, S., Lampropoulou, V., Roch, T., Lawrie, S., et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 209:5 (2012), 1001–1010.
7. Trinschek, B., Luessi, F., Haas, J., Wildemann, B., Zipp, F., Wiendl, H., et al. Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis. PLoS ONE, 8(10), 2013, e77634.
8. Ogura, H., Murakami, M., Okuyama, Y., Tsuruoka, M., Kitabayashi, C., Kanamoto, M., et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29:4 (2008), 628–636.
9. Teachey, D.T., Lacey, S.F., Shaw, P.A., Melenhorst, J.J., Maude, S.L., Frey, N., et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6:6 (2016), 664–679.
10. Brudno, J.N., Somerville, R.P., Shi, V., Rose, J.J., Halverson, D.C., Fowler, D.H., et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol 34:10 (2016), 1112–1121.
11. Laport, G.G., Levine, B.L., Stadtmauer, E.A., Schuster, S.J., Luger, S.M., Grupp, S., et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 102:6 (2003), 2004–2013.
12. Singh, N., Liu, X., Hulitt, J., Jiang, S., June, C.H., Grupp, S.A., et al. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol Res 2:11 (2014), 1059–1070.
13. Han, T.H., Jin, P., Ren, J., Slezak, S., Marincola, F.M., Stroncek, D.F., Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma. J Immunother 32:4 (2009), 399–407.
14. Singh, N., Kulikovskaya, I., Barrett, D.M., Binder-Scholl, G., Jakobsen, B., Martinez, D., et al. T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. Oncoimmunology, 5(1), 2016, e1040216.
15. Mitsuyasu, R.T., Anton, P.A., Deeks, S.G., Scadden, D.T., Connick, E., Downs, M.T., et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96:3 (2000), 785–793.
16. Deeks, S.G., Wagner, B., Anton, P.A., Mitsuyasu, R.T., Scadden, D.T., Huang, C., et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 5:6 (2002), 788–797.
17. Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12:20 Pt 1 (2006), 6106–6115.
18. Lamers, C.H., Langeveld, S.C., Groot-van Ruijven, C.M., Debets, R., Sleijfer, S., Gratama, J.W., Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother 56:12 (2007), 1875–1883.
19. Lee, D.W., Gardner, R., Porter, D.L., Louis, C.U., Ahmed, N., Jensen, M., et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:2 (2014), 188–195.
20. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:16 (2014), 1507–1517.
21. Barrett, D.M., Liu, X., Jiang, S., June, C.H., Grupp, S.A., Zhao, Y., Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 24:8 (2013), 717–727.
22. Teachey, D.T., Rheingold, S.R., Maude, S.L., Zugmaier, G., Barrett, D.M., Seif, A.E., et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121:26 (2013), 5154–5157.
23. Rapoport, A.P., Stadtmauer, E.A., Binder-Scholl, G.K., Goloubeva, O., Vogl, D.T., Lacey, S.F., et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 21:8 (2015), 914–921.
24. Ellebrecht, C.T., Bhoj, V.G., Nace, A., Choi, E.J., Mao, X., Cho, M.J., et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353:6295 (2016), 179–184.